The following list of outpatient medications covered under Medicare Part B (i.e., drugs that are delivered in the physician's office, clinic, outpatient or home setting) require preauthorization prior to being provided or administered. This list does not include drugs that process under the Medicare Part D pharmacy benefit, such as self-administered drugs or oral medications. Coverage will be provided for Part B medical drugs when it is determined to be medically necessary, in accordance with Centers for Medicare & Medicaid Services (CMS) guidelines (Available at: http://www.cms.gov/medicare-coverage-database).

Coverage of these outpatient medications is based on existing National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs), and other relevant sources. Adherence to these policies are required when they exist. The table below lists drug names, HCPCS codes, applicable Medicare policies, and *Step Therapy Program requirements. For drugs, which do not have an applicable NCD, LCD, or LCA, there may be a clinical resource. In the absence of Medicare coverage guidance (NCDs, LCDs, etc.), CMS allows Medicare Advantage plans to implement their criteria for coverage with the guidance and review of a Drug Committee. Please refer to the published clinical policy on Aspire Health's website under Part B drugs.

*Some Part B drugs may also require **step therapy** before they will be covered. Prior authorization will be required in these cases. Contraindication, intolerance, or a prior trial and failure with a preferred drug in the same class or category may be required, amongst other criteria. Step therapy is required when indicated in the 'Step Therapy Program' column of the table below.

This list is subject to change. Please review this list periodically for updates. Aspire Health reserves the right to revise, update, and/or add/remove drugs as new drugs are FDA-approved and become available for use.

Part B Prior Authorization Drug List Program (Effective 1/1/2024)						
DRUG	HCPCS	Medicare Policies (NCD, LCD, LCA)	Clinical Resource for Drugs without NCDs/ LCDs/LCAs	Step Therapy Program		
	ANTI-AMYLOID AGENTS (ALZHEIMER DISEASE)					
Leqembi (lecanemab-irmb)	J0174	<u>NCD</u>	Aspire Clinical Policy	No		
Aduhelm (aducanumab)	J0172	NCD	Aspire Clinical Policy	No		
VASCULAR ENDOTH	VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR (RETINAL DISORDERS AGENTS)					
*Eylea (aflibercept)	J0178		Aspire Clinical Policy	Yes (*exceptions apply)		
Lucentis (ranibizumab)	J2778		Aspire Clinical Policy	Yes		
Byooviz (ranibizumab-nuna)	Q5124		Aspire Clinical Policy	Yes		
Cimerli (ranibizumab-eqrn)	J3590		Aspire Clinical Policy	Yes		

Prior Authorization (PA): Approval is required needed from the plan is required before the drug is covered. This requirement helps ensure medication safety and helps guide the appropriate use of certain drugs.

			T			
Susvimo (ranibizumab implant)	J2779	Aspire Clinical Policy	Yes			
Beovu (brolucizumab-dbll)	J0179	Aspire Clinical Policy	Yes			
Vabysmo (faricimab)	J2777	Aspire Clinical Policy	Yes			
	Intra-articular Corticosteroids (Osteoarthritis)					
Methylprednisolone acetate injection (Depo-Medrol)	J1020 J1030 J1040 J2920 J2930	No PA required	No			
Triamcinolone acetonide injection (Kenalog)	J3301 J3302 J3303	No PA required	No			
Zilretta (triamcinolone acetonide ER)	J3304	Aspire Clinical Policy	Yes			
F	Hyaluronic Acids / Viscosupplements (Osteoarthritis)					
Durolane	J7318	Aspire Clinical Policy	Yes			
Gel-One	J7326	Aspire Clinical Policy	Yes			
Monovisc	J7327	Aspire Clinical Policy	Yes			
Synvisc-One	J7325	Aspire Clinical Policy	Yes			
VISCO-3	J7321	Aspire Clinical Policy	Yes			
Euflexxa	J7323	Aspire Clinical Policy	Yes			
GelSyn-3	J7328	Aspire Clinical Policy	Yes			
Hyalgan, Supartz, Supartz FX,	J7321	Aspire Clinical Policy	Yes			
GenVisc 850	J7320	Aspire Clinical Policy	Yes			
Hymovis	J7322	Aspire Clinical Policy	Yes			
Orthovisc	J7324	Aspire Clinical Policy	Yes			

Prior Authorization (PA): Approval is required needed from the plan is required before the drug is covered. This requirement helps ensure medication safety and helps guide the appropriate use of certain drugs.

0 : 1	17004		A . OII . LD II	V		
Synojoynt	J7331		Aspire Clinical Policy	Yes		
Synvisc	J7325		Aspire Clinical Policy	Yes		
Triluron	J7332		Aspire Clinical Policy	Yes		
	Bone Density Agents (Osteoporosis)					
Bisphosphonates (IV): • Zoledronic acid (Reclast) • Ibandronate (Boniva)	J3489; J1740		No PA required	No		
Prolia (denosumab)	J0897		Aspire Clinical Policy	Yes		
Evenity (romosozumab)	J3111		Aspire Clinical Policy	Yes		
	Multiple Sclerosis (Infusion)					
Tysabri (natalizumab)	J2323		Aspire Clinical Policy	Yes		
Ocrevus (ocrelizumab)	J2350		Aspire Clinical Policy	Yes		
Lemtrada (alemtuzumab)	J0202		Aspire Clinical Policy	Yes		
		Infliximab Products				
Remicade (infliximab)	J1745		Aspire Clinical Policy	Yes		
Infliximab	J1745		Aspire Clinical Policy	Yes		
Inflectra (infliximab-dyyb)	Q5103		Aspire Clinical Policy	Yes		
Avsola (infliximab-axxq)	Q5121		Aspire Clinical Policy	Yes		
Renflexis (infliximab-abda)	Q5104		Aspire Clinical Policy	Yes		
Rituximab Products						
Rituxan (rituximab)	J9312		Aspire Clinical Policy	Yes		
Rituxan Hycela (rituximab and hyaluronidase)	J9311		Aspire Clinical Policy	Yes		
Ruxience (rituximab-pvvr)	Q5119		Aspire Clinical Policy	Yes		

Prior Authorization (PA): Approval is required needed from the plan is required before the drug is covered. This requirement helps ensure medication safety and helps guide the appropriate use of certain drugs.

Truxima (rituximab-abbs)	Q5115	Aspire Clinical Policy	Yes
Riabni (rituximab-arrx)	Q5123	Aspire Clinical Policy	Yes

Medicare covers outpatient (Part B) drugs that are furnished "incident to" a physician's service provided that the drugs are not usually self-administered by the patients who take them. See the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals at: http://www.cms.hhs.gov/manuals/Downloads/bp102c15.pdf.

This Medicare Part B Prior Authorization Drug List is provided for informational purposes only and neither constitutes nor replaces professional medical advice. Physicians, hospitals, and other providers are expected to administer or use drugs/biologicals in the most effective and clinically appropriate manner. Treating physicians and other health care providers are solely responsible for all medical care decisions. In accordance with the member's Evidence of Coverage (EOC), every benefit plan has its own coverage provisions, limitations, and exclusions. In the event of a conflict between this policy and the member's EOC, the member's EOC provisions will take precedence.

The inclusion of a code in this policy does not imply that the health service it describes is covered or not covered. Benefit coverage for health services is determined by the member-specific plan document and applicable laws that may mandate coverage for a particular service. Inclusion of a code does not imply or guarantee reimbursement or payment of a claim. Other Policies and Standards may also apply. Providers are expected to retain or have access to the necessary documentation when requested in order to support coverage.

References

- 1. Medicare Managed Care Manual, Chapter 4, §90.5.
- 2. Centers for Medicare and Medicaid Services, Medicare Advantage Prior Authorization and Step Therapy for Part B Drugs. August 7, 2018. Available online at: http://cms.gov.
- 3. Centers for Medicare and Medicaid Services, Internet-Only Medicare Benefit Policy Manual, CMS Pub. 100-02, Chapter 15, Sec. 50. Available online at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Internet-Only-Manuals-IOMs

Prior Authorization (PA): Approval is required needed from the plan is required before the drug is covered. This requirement helps ensure medication safety and helps guide the appropriate use of certain drugs.